NCLEX Review Guide: Amyotrophic Lateral Sclerosis (ALS)

Disease Process

• Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of both upper and lower motor neurons in the brain, brainstem, and spinal cord. This degeneration leads to progressive muscle weakness, atrophy, and eventual paralysis while typically sparing cognitive function.
• The etiology is multifactorial with approximately 5-10% of cases being familial (genetic) with mutations in genes such as SOD1, C9orf72, and FUS, while 90-95% are sporadic with no clear genetic linkage.

Clinical Manifestations

• Upper motor neuron signs include hyperreflexia, spasticity, and positive Babinski sign, resulting from damage to corticospinal tracts in the brain and spinal cord.
• Lower motor neuron signs include muscle weakness, atrophy, fasciculations, and hyporeflexia, resulting from damage to anterior horn cells in the spinal cord and brainstem nuclei.
• Initial symptoms often begin asymmetrically and may include limb weakness (70% of patients), bulbar symptoms like dysarthria and dysphagia (25%), or respiratory symptoms (5%).

Diagnostic Criteria

• ALS diagnosis is primarily clinical, based on the El Escorial criteria, which requires evidence of both upper and lower motor neuron degeneration with progressive spread of symptoms.
• Diagnostic workup includes electromyography (EMG) and nerve conduction studies (NCS) to detect denervation, MRI to rule out other conditions, and laboratory tests to exclude mimicking disorders.

Nursing Assessment

• Complete a thorough neurological assessment, focusing on motor strength, deep tendon reflexes, presence of fasciculations, muscle tone, and bulbar function (speech, swallowing).
• Assess respiratory function through vital capacity measurements, oxygen saturation, and signs of respiratory distress, as respiratory compromise is a leading cause of mortality.
• Evaluate nutritional status, weight changes, and ability to safely consume food and fluids due to progressive dysphagia.

Pharmacological Management

• Riluzole (Rilutek) is FDA-approved for ALS and works by reducing glutamate excitotoxicity, potentially extending survival by 2-3 months. The standard dose is 50 mg twice daily, with side effects including elevated liver enzymes, fatigue, and nausea.
• Edaravone (Radicava) is another FDA-approved medication that acts as a free radical scavenger, potentially slowing functional decline in early-stage ALS. It is administered as an IV infusion in 28-day cycles.
• Symptom management medications include baclofen or dantrolene for spasticity, quinine or carbamazepine for cramps, anticholinergics for excessive secretions, and opioids for pain and dyspnea.

Respiratory Management

• Non-invasive positive pressure ventilation (NIPPV) is recommended when forced vital capacity falls below 50% of predicted or when patients exhibit symptoms of nocturnal hypoventilation. NIPPV can improve quality of life and potentially extend survival.
• Mechanical ventilation via tracheostomy may be considered in advanced disease, but requires extensive discussion regarding goals of care and quality of life implications.

Nutritional Management

• Percutaneous endoscopic gastrostomy (PEG) tube placement is recommended when patients experience significant weight loss (>10% of body weight), prolonged mealtimes, or recurrent aspiration due to dysphagia.
• Dietary modifications include soft, pureed foods, thickened liquids, and high-calorie supplements to maintain adequate nutrition and prevent weight loss.

Multidisciplinary Care

• ALS management requires a comprehensive multidisciplinary approach involving neurologists, pulmonologists, gastroenterologists, speech therapists, physical therapists, occupational therapists, respiratory therapists, dietitians, social workers, and palliative care specialists.
• Specialized ALS clinics have been shown to improve quality of care and potentially extend survival through coordinated, expert management.

Respiratory Care

1. Assess respiratory status, including respiratory rate, depth, pattern, and use of accessory muscles at each encounter.
2. Monitor oxygen saturation and teach patients/caregivers to use pulse oximetry at home.
3. Provide chest physiotherapy and postural drainage techniques to mobilize secretions.
4. Teach proper use of suction equipment for secretion management.
5. Assist with NIPPV management, including proper mask fitting, skin care, and troubleshooting.

Nutrition and Dysphagia Management

1. Implement dysphagia precautions based on speech therapy recommendations.
2. Position patient upright at 90 degrees during meals and remain upright for 30 minutes after eating.
3. Provide small, frequent meals with appropriate texture modifications.
4. Teach caregivers proper techniques for feeding and managing PEG tubes if present.
5. Monitor weight regularly and document nutritional intake.

Communication Support

• As dysarthria progresses, implement alternative and augmentative communication (AAC) devices ranging from simple letter boards to eye-gaze technology and voice banking.
• Collaborate with speech therapists to identify the most appropriate communication strategies based on the patient's abilities and disease stage.

Mobility and Skin Care

• Implement a regular turning schedule for bed-bound patients, typically every 2 hours, to prevent pressure injuries.
• Collaborate with physical and occupational therapists to maintain functional mobility as long as possible through appropriate exercises and assistive devices.
• Perform regular skin assessments, paying particular attention to bony prominences and areas at risk for pressure injury.

ALS vs. Primary Lateral Sclerosis (PLS)

• ALS affects both upper and lower motor neurons, while PLS affects only upper motor neurons, resulting in spasticity without muscle atrophy or fasciculations.
• PLS has a much slower progression and better prognosis than ALS, with survival often extending decades rather than years.

ALS vs. Progressive Bulbar Palsy

• Progressive bulbar palsy is actually a form of ALS that initially affects the bulbar muscles (speech, swallowing), but eventually progresses to generalized ALS in most cases.
• Patients with initial bulbar symptoms typically have a shorter survival time than those with limb-onset ALS.

NCLEX Strategy for ALS Questions

• Focus on prioritizing respiratory management, as respiratory failure is the leading cause of death.
• Remember that ALS preserves cognition and sensation, so patients remain aware and can feel pain.
• Questions often focus on multidisciplinary care coordination and quality of life interventions.
• Look for questions addressing communication strategies as speech deteriorates.

Common Pitfalls

• Don't confuse ALS with MS - ALS primarily affects motor function while preserving sensation, whereas MS affects both motor and sensory functions.
• Remember that ALS patients maintain cognitive function and awareness even as physical abilities decline, necessitating appropriate communication strategies.
• Avoid assuming all ALS patients will want the same interventions - decisions about PEG tubes, ventilation, and end-of-life care are highly personal.

Disease Education

• Provide clear, honest information about the progressive nature of ALS while maintaining hope through quality of life interventions.
• Explain that cognitive function typically remains intact, and patients can continue to participate in decision-making throughout the disease course.
• Direct patients and families to reliable resources such as the ALS Association, Muscular Dystrophy Association, and peer support groups.

Caregiver Training

• Teach proper body mechanics for transfers and positioning to prevent caregiver injury.
• Provide training on equipment use, including feeding tubes, suction machines, and ventilatory support devices.
• Emphasize the importance of caregiver self-care and utilizing respite services to prevent burnout.

Advance Care Planning

• Facilitate discussions about advance directives, healthcare proxies, and end-of-life preferences early in the disease course.
• Provide information about hospice services and palliative care options to support quality of life.
• Discuss ventilation options and their implications before respiratory crisis occurs.

Knowledge Check

• I can explain the pathophysiology of ALS, including upper and lower motor neuron involvement.
• I can list the major clinical manifestations of ALS and differentiate them from other neurological disorders.
• I understand the pharmacological management of ALS, including medication mechanisms and side effects.
• I can describe appropriate respiratory management interventions for ALS patients.
• I can identify appropriate nutritional interventions for patients with dysphagia.
• I understand the multidisciplinary approach to ALS management.
• I can explain important patient and family education points for ALS care.
• I can differentiate ALS from other neurological conditions like MS and GBS.